Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | NTSR2 | O95665 | 9/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 9/20 | 0.47 |
| ▸ | SORT1 | Q99523 | 7/20 | 0.47 |
| ▸ | NRP1 | O14786 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.42 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | GRB2 | P62993 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30811213 | 0.93 | NMUR2 (0.48) | F2NTSR2NTSR1NRP1OPRM1 | |
| SCHEMBL29802257 | 0.88 | NRP1 (0.53) | F2NTSR2NTSR1SORT1NRP1 | |
| SCHEMBL31039951 | 0.87 | OPRM1 (0.56) | F2NTSR2NTSR1SORT1NRP1 | |
| SCHEMBL31746145 | 0.85 | OPRM1 (0.56) | F2NTSR2NTSR1SORT1OPRM1 | |
| SCHEMBL29801929 | 0.84 | GRB2 (0.51) | F2NTSR2NTSR1SORT1NRP1 | |
| SCHEMBL31018311 | 0.84 | CXCR4 (0.47) | OPRM1NMUR2NMUR1 | |
| SCHEMBL7753982 | 0.84 | F2 (0.51) | F2NTSR2NTSR1SORT1OPRM1 | |
| SCHEMBL7753988 | 0.84 | F2 (0.51) | F2NTSR2NTSR1SORT1OPRM1 | |
| SCHEMBL30595824 | 0.84 | ACE (0.45) | F2NRP1OPRM1ACEGRB2 | |
| SCHEMBL30595823 | 0.84 | ACE (0.45) | F2NRP1OPRM1ACEGRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | F2 1449/4885NTSR2 257/4885NTSR1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.